Ginkgo biloba L. flavonoids inhibit CYP 2A5; potential dietary supplement for nicotine replacement therapy enhancement

References

• Akrodou YM. 2015. CYP2A6 polymorphisms may strengthen individualized treatment for nicotine dependence. Scientifica (Cairo) 2015:491514.
   PubMed Web of Science ®Google Scholar
• Cao L, Kwara A, Greenblatt DJ. 2017. Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 69(12):1762–1772.
   PubMed Web of Science ®Google Scholar
• Chan J, Oshiro T, Thomas S, Higa A, Black S, Todorovic A, Elbarbry F, Harrelson JP. 2016. Inactivation of CYP2A6 by the dietary phenylpropanoid trans-cinnamic aldehyde (cinnamaldehyde) and estimation of interactions with nicotine and letrozole. Drug Metab Dispos. 44(4):534–543.
   PubMed Web of Science ®Google Scholar
• Chen LS, Bloom AJ, Baker TB, Smith SS, Piper ME, Martinez M, Saccone N, Hatsukami D, Goate A, Bierut L. 2014. Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). Addiction. 109(1):128–137.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhong W, Shu C, Yang H, Li E. 2020. Comparative analysis of chemical constituents and bioactivities of the extracts from leaves, seed coats and embryoids of Ginkgo biloba L. Nat Prod Res. :1–4.
   Web of Science ®Google Scholar
• Colilla S, Lerman C, Shields PG, Jepson C, Rukstalis M, Berlin J, DeMichele A, Bunin G, Strom BL, Rebbeck TR. 2005. Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenet Genomics. 15(6):393–398.
   PubMed Web of Science ®Google Scholar
• EMEA. 2014. Committee on Herbal Medicinal Products (HMPC). Assessment report on Ginkgo biloba L., folium. EMA/HMPC/321095/2012, dated Jan 28.
   Google Scholar
• EMEA. 2015. Committee on Herbal Medicinal Products (HMPC). European Union herbal monograph on Ginkgo biloba L., folium. EMA/HMPC/321097/2012, dated Jan 28.
   Google Scholar
• Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. 2018. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 5:CD000146.
   PubMedGoogle Scholar
• Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC. 2007. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol. 45(11):2179–2205.
   PubMed Web of Science ®Google Scholar
• Koenigs LL, Peter RM, Thompson SJ, Rettie AE, Trager WF. 1997. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab Dispos. 25(12):1407–1415.
   PubMed Web of Science ®Google Scholar
• Messina ES, Tyndale RF, Sellers EM. 1997. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther. 282(3):1608–1614.
   PubMed Web of Science ®Google Scholar
• Mohanta TK, Tamboli Y, Zubaidha PK. 2014. Phytochemical and medicinal importance of Ginkgo biloba L. Nat Prod Res. 28(10):746–752.
   PubMed Web of Science ®Google Scholar
• Murphy SE, Raulinaitis V, Brown KM. 2005. Nicotine 5'-oxidation and methyl oxidation by P450 2A enzymes. Drug Metab Dispos. 33(8):1166–1173.
   PubMed Web of Science ®Google Scholar
• Mwenifumbo JC, Tyndale RF. 2007. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics. 8(10):1385–1402.
   PubMed Web of Science ®Google Scholar
• Pan Y, Zheng W, Yang S. 2020. Chemical and activity investigation on metabolites produced by an endophytic fungi Psathyrella candolleana from the seed of Ginkgo biloba. Nat Prod Res. 34(21):3130–3133.
   PubMed Web of Science ®Google Scholar
• Pang CY, Mak JW, Ismail R, Ong CE. 2012. In vitro modulatory effects of flavonoids on human cytochrome P450 2C8 (CYP2C8). Naunyn Schmiedebergs Arch Pharmacol. 385(5):495–502.
   PubMed Web of Science ®Google Scholar
• Prochaska JJ, Benowitz NL. 2016. The past, present, and future of nicotine addiction therapy. Annu Rev Med. 67:467–486.
   PubMed Web of Science ®Google Scholar
• Raunio H, Pokela N, Puhakainen K, Rahnasto M, Mauriala T, Auriola S, Juvonen RO. 2008. Nicotine metabolism and urinary elimination in mouse: in vitro and in vivo. Xenobiotica. 38(1):34–47.
   PubMed Web of Science ®Google Scholar
• Raunio H, Rahnasto-Rilla M. 2012. CYP2A6: genetics, structure, regulation, and function. Drug Metabol Drug Interact. 27(2):73–88.
   PubMedGoogle Scholar
• Sellers EM, Kaplan HL, Tyndale RF. 2000. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin Pharmacol Ther. 68(1):35–43.
   PubMed Web of Science ®Google Scholar
• Sellers EM, Tyndale RF, Fernandes LC. 2003. Decreasing smoking behaviour and risk through CYP2A6 inhibition. Drug Discov Today. 8(11):487–493.
   PubMed Web of Science ®Google Scholar
• Siu EC, Wildenauer DB, Tyndale RF. 2006. Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5. Psychopharmacology (Berl) 184(3–4):401–408.
   PubMed Web of Science ®Google Scholar
• Tanner JA, Tyndale RF. 2017. Variation in CYP2A6 activity and personalized medicine. J Pers Med. 7(4):18.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xie X, Liu L, Zhang H, Ni F, Wen J, Wu Y, Wang Z, Xiao W. 2019. Four new flavonol glycosides from the leaves of Ginkgo biloba. Nat Prod Res. 35(15):1–6.
   PubMed Web of Science ®Google Scholar
• WHO. 2018. Tobacco breask hearts: choose health not tobacco.
   Google Scholar
• Xi ZX, Spiller K, Gardner EL. 2009. Mechanism-based medication development for the treatment of nicotine dependence. Acta Pharmacol Sin. 30(6):723–739.
   PubMed Web of Science ®Google Scholar
• Zhu BT, Liehr JG. 1996. Inhibition of catechol O-methyltransferase-catalyzed O-methylation of 2- and 4-hydroxyestradiol by quercetin. Possible role in estradiol-induced tumorigenesis. J Biol Chem. 271(3):1357–1363.
   PubMed Web of Science ®Google Scholar